| Literature DB >> 35907940 |
Zhenyu Wang1,2, Pei Zhang1,2, Chen Huang1,2,3, Yining Guo1,2, Xuhe Dong1,2, Xuemin Li4,5.
Abstract
BACKGROUND: The use of antibiotics preoperatively is effective to decrease the incidence of ocular bacterial infections but may lead to high resistance rate, especially on patients with multi-risk clinical factors. This study systematically analyzed real-world data (RWD) of patients to reveal the association between clinical factors and conjunctival sac bacterial load and offer prophylaxis suggestions.Entities:
Keywords: Antibiotic prophylactic therapy; Clinical factor; Levofloxacin; Real world study
Mesh:
Substances:
Year: 2022 PMID: 35907940 PMCID: PMC9338605 DOI: 10.1186/s12886-022-02544-2
Source DB: PubMed Journal: BMC Ophthalmol ISSN: 1471-2415 Impact factor: 2.086
Clinical factors related to conjunctival sac bacterial load in patients before cataract surgery
| Conjunctival sac bacterial culture | χ2 | |||
|---|---|---|---|---|
| Positive ( | Negative ( | |||
| Sex | ||||
| Male | 137(50.0%) | 5729(37.8%) | 16.888 | < 0.001*a |
| Female | 137(50.0%) | 9412(62.2%) | ||
| Hypertension | ||||
| Yes | 149(54.4%) | 5811(38.4%) | 29.054 | < 0.001* |
| No | 125(45.6%) | 9330(61.6%) | ||
| Diabetes mellitus | ||||
| Yes | 88(32.1%) | 3405(22.5%) | 14.236 | < 0.001* |
| No | 186(67.9%) | 11,736(77.5%) | ||
| History of hospital-based surgeries | ||||
| Yes | 131(47.8%) | 7424(49.0%) | 0.161 | 0.688 |
| No | 143(52.2%) | 7717(51.0%) | ||
a*P < 0.05 in two-side χ2 test
bn: number of patients
Binary logistic regression analysis of positive conjunctival sac bacterial culture in patients before cataract surgery based on clinical factors
| Bb | SEb | Waldb | d | Odds Ratio | 95%CI for Odds Ratiob | |||
|---|---|---|---|---|---|---|---|---|
| Lower | Upper | |||||||
| Sexa | 0.517 | 0.122 | 17.849 | 1 | < 0.001*c | 1.677 | 1.319 | 2.131 |
| Hypertension | 0.612 | 0.127 | 23.378 | 1 | < 0.001* | 1.844 | 1.439 | 2.364 |
| Diabetes mellitus | 0.326 | 0.135 | 5.825 | 1 | 0.016* | 1.385 | 1.063 | 1.805 |
| History of hospital-based surgeries | -0.125 | 0.123 | 1.029 | 1 | 0.31 | 0.883 | 0.694 | 1.123 |
| Constant | -4.55 | 0.124 | 1344.781 | 1 | < 0.001* | 0.011 | ||
aSex is for males compared to females
bB regression coefficient, SE standard error of the mean, Wald Wald test score, df degree of freedom, 95% CI of OR 95% confidence interval of odds ratio
c*P < 0.05 in binary logistic regression analysis
Summary of conjunctival sac bacteria of the patients who had undergone bilateral operations
| Patient | Sex | Age (y) | Left/Right | Operation | Isolated bacteria | Zoom diameter of K-B test of antimicrobial agent (mm) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tobramycin | Ceftriaxone | Erythromycin | Vancomycin | Levofloxacin | Ofloxacin | Rifampin | ||||||
| 1 | Male | 67 | OD | 2018/9/10 | - | 34 | 12 | 23 | 22 | 20 | 32 | |
| OS | 2018/10/11 | Unidentifiable bacteria | 16 | 28 | 10 | 30 | 30 | 24 | 34 | |||
| 2 | Female | 75 | OD | 2017/6/7 | 10 | 10 | 7 | 8 | 14 | 12 | 15 | |
| OS | 2018/5/24 | Unidentifiable bacteria | 10 | 24 | - | 14 | 9 | 9 | 30 | |||
| 3 | Female | 72 | OD | 2017/12/7 | Inactive biochemical spectrum | - | 16 | 16 | 20 | 7 | 7 | 28 |
| OS | 2018/1/14 | - | 28 | 17 | 22 | - | - | 28 | ||||
Fig. 1A Number of culture-positive samples for the top 10 identified bacterial strains. B Pie graphs showing the percentage of postoperative endophthalmitis for the three most common isolates
Number of isolated bacteria and K-B test results
| Isolated bacteria | Number of K-Bb test results | Zone Diameter of Antimicrobial agent (mm) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Tobramycin | Ceftriaxone | Erythromycin | Vancomycin | Levofloxacin | Ofloxacin | Rifampin | ||||
| 76(27.7%) | ||||||||||
| | 56(20.4%) | 40 | 7(0) | 22.5(19.25) | 0(0) | 15(14) | 10.5(0) | 7(0) | 30(28) | < 0.001*c |
| | 7(2.6%) | 2 | 7(0) | 23.5(23) | 8.5(7) | 19.5(19) | 21(12) | 20.5(12) | 35(34) | - |
| | 4(1.5%) | 3 | 0(0) | 20(18) | 24(7) | 14(12) | 18(15) | 18(11) | 24(20) | - |
| | 2(0.7%) | 1 | 13 | 18 | 0 | 17 | 10 | 0 | 30 | - |
| | 1(0.4%) | 0 | ||||||||
| | 1(0.4%) | 1 | 20 | 22 | 26 | 15 | 22 | 20 | 30 | - |
| | 1(0.4%) | 1 | 20 | 26 | 30 | 12 | 22 | 22 | 28 | - |
| | 1(0.4%) | 0 | ||||||||
| | 1(0.4%) | 1 | 12 | 18 | 0 | 15 | 0 | 0 | 28 | - |
| | 1(0.4%) | 1 | 18 | 32 | 20 | 16 | 12 | 12 | 30 | - |
| | 1(0.4%) | 1 | 20 | 22 | 22 | 14 | 20 | 16 | 24 | - |
| 67(24.5%) | ||||||||||
| | 37(13.5%) | 35 | 20(11) | 28(24) | 14(8) | 21(20) | 0(0) | 0(0) | 30(28) | < 0.001* |
| | 19(6.9%) | 18 | 11(0) | 28(23.5) | 15(0) | 24(18) | 20(0) | 16.5(0) | 30(24.75) | < 0.001* |
| | 11(4.0%) | 10 | 21(17.5) | 22(17.5) | 15.5(0) | 24(20) | 15(10.25) | 18(11.5) | 33.5(29.5) | < 0.001* |
| 39(14.2%) | ||||||||||
| | 32(11.7%) | 29 | 11(8) | 30(27) | 12(8) | 20(18) | 20(16) | 18(14) | 30(29) | < 0.001* |
| | 7(2.6%) | 7 | 13(10) | 26(20) | 10(8) | 16(14) | 18(14) | 14(14) | 30(28) | < 0.001* |
| 12(4.4%) | ||||||||||
| | 9(3.3%) | 5 | 20(14) | 14(5) | 8(3.5) | 9(8.5) | 14(7) | 13(11.5) | 20(15.5) | - |
| | 1(0.4%) | 0 | ||||||||
| | 1(0.4%) | 1 | 11 | 18 | 16 | 10 | 16 | 15 | 11 | - |
| | 1(0.4%) | 1 | 24 | 24 | 24 | 8 | 22 | 24 | 20 | - |
| 9(3.3%) | ||||||||||
| | 4(1.5%) | 4 | 8.5(0) | 26(15) | 18(14.5) | 19(11.25) | 18(15.25) | 8(0) | 28(17.5) | - |
| | 3(1.1%) | 3 | 7(0) | 33(30) | 30(15) | 20(18) | 20(19) | 17(15) | 26(24) | - |
| | 1(0.4%) | 1 | 7 | 24 | 0 | 12 | 14 | 12 | 24 | - |
| | 1(0.4%) | 1 | 10 | 24 | 0 | 14 | 9 | 9 | 30 | - |
| 8(2.9%) | 8 | 23(18.5) | 31(26.5) | 11(8.25) | 14(12.25) | 15(10.25) | 12.5(0) | 29(21.25) | 0.003* | |
| 7(2.6%) | ||||||||||
| | 6(2.2%) | 6 | 6(0) | 25(19) | 20(11.75) | 13.5(11.75) | 19(12.25) | 14.5(7.5) | 30(22.25) | 0.024* |
| | 1(0.4%) | 1 | 0 | 24 | 22 | 16 | 24 | 22 | 28 | - |
| 3(1.1%) | ||||||||||
| | 2(0.7%) | 2 | 15.5(15) | 22(20) | 12.5(11) | 0(0) | 12(7) | 7.5(0) | 15(15) | - |
| | 1(0.4%) | 1 | 22 | 0 | 8 | 21 | 22 | 22 | 30 | - |
| 53(19.3%) | ||||||||||
| Inactive biochemical spectrum | 14(5.1%) | 14 | 12(0) | 30(16.75) | 16(12) | 20(9.5) | 11(0) | 8.5(0) | 27(15.5) | 0.001* |
| Unidentifiable bacteria | 14(5.1%) | 12 | 19(14.5) | 29.5(24.5) | 17.5(10.5) | 19(9.5) | 23(17.75) | 16(11) | 26.5(17) | 0.008* |
| | 4(1.5%) | 4 | 5(0) | 31(21) | 18(10.25) | 23.5(22) | 18(4) | 7(0) | 35.5(16) | - |
| | 3(1.1%) | 3 | 8(0) | 26(14) | 17(10) | 22(18) | 32(18) | 14(0) | 30(28) | - |
| | 3(1.1%) | 3 | 14(9) | 26(22) | 15(10) | 20(20) | 22(16) | 14(0) | 26(20) | - |
| | 2(0.7%) | 2 | 12(0) | 32.5(28) | 17(0) | 20(16) | 24(16) | 19.5(13) | 26(18) | - |
| | 2(0.7%) | 2 | 20(18) | 23(22) | 19(19) | 12.5(9) | 28.5(27) | 25.5(24) | 21.5(20) | - |
| | 2(0.7%) | 2 | 8(0) | 21(14) | 5(0) | 23.5(17) | 19(8) | 12(0) | 29(24) | - |
| | 1(0.4%) | 1 | 16 | 24 | 26 | 20 | 20 | 0 | 30 | - |
| | 1(0.4%) | 1 | 11 | 20 | 8 | 18 | 10 | 10 | 20 | - |
| | 1(0.4%) | 1 | 0 | 19 | 0 | 0 | 0 | 0 | 0 | - |
| | 1(0.4%) | 1 | 13 | 0 | 20 | 16 | 18 | 15 | 0 | - |
| | 1(0.4%) | 1 | 13 | 21 | 0 | 0 | 20 | 16 | 9 | - |
| | 1(0.4%) | 1 | 0 | 30 | 16 | 15 | 12 | 0 | 28 | - |
| | 1(0.4%) | 0 | ||||||||
| | 1(0.4%) | 1 | 24 | 18 | 14 | 0 | 18 | 16 | 12 | - |
| | 1(0.4%) | 1 | 0 | 0 | 11 | 0 | 20 | 20 | 0 | - |
an(%): number of patients (percentage in the culture-positive group)
bK-B: Kirby-Bauer
c*P < 0.05 in the Kruskal–Wallis H test
Results of K-B test of Staphylococcus spp
| Antimicrobial agent | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| na | 56 | 7 | 4 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Number of K-Bb test results | 46 | 3 | 3 | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | |
| Tobramycin | Rc | 25 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Ic | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Sc | 15 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | |
| Ceftriaxone | R | 14 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| I | 7 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| S | 19 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | |
| Erythromycin | R | 29 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| I | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
| S | 9 | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | |
| Vancomycin | R | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| I | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| S | 40 | 2 | 3 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | |
| Levofloxacin | R | 34 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| I | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| S | 5 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | |
| Ofloxacin | R | 35 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| I | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
| S | 5 | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | |
| Rifampin | R | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| I | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| S | 38 | 2 | 3 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 |
an: number of patients
bK-B test: Kirby-Bauer disk diffusion test
cR: resistance I: intermediate S: susceptible
Fig. 2Upsetview of multidrug resistance of Staphylococcus epidermidis
Fig. 3Violin plot of K-B test of Staphylococcus epidermidis against Rifampin. Each red line represents the median of each subgroup
Summary of studies on conjunctival swab culture in cataract patients preoperatively without using antibiotic drops in the eyes
| Year of Publication | Patients/eye number | Positive rate of cultured samples | Major Pathogen | References |
|---|---|---|---|---|
| 1999 | 49 patients/49 eyes | 69.4% | Tervo et al. [ | |
| 2003 | 100 patients/100 eyes | 74.0% (twenty six of the 100 cultures were “sterile”) | Coagulase-negative | Ferguson et al. [ |
| 2012 | 56 patients/112 eyes | 48.3% (54 eyes) | Coagulase-negative | Keshav et al. [ |
Summary of major pathogens involved in post-cataract surgery endophthalmitis
| Year of Publication | Major Pathogen | References |
|---|---|---|
| 2005 | Kenchappa et al. [ | |
| 2009 | Pinna et al. [ | |
| 2009 | Horster et al. [ | |
| 2011 | Gram-positive bacteria (65.2%) | Ding et al. [ |
| 2013 | Coagulase-negative | Durand [ |
| 2015 | Coagulase-negative | Chiquet et al. [ |
| 2015 | Ji et al. [ | |
| 2015 | Priya et al. [ | |
| 2017 | Coagulase-negative | Durand [ |
| 2017 | Gram-positive bacteria (96%, Coagulase-negative | Slean et al. [ |
| 2018 | Gram-positive bacteria (95%), including Coagulase-negative | Rahmani et al. [ |
| 2018 | Gram-negative bacteria (5%), including | Rahmani et al. [ |
| 2019 | Gram-positive bacteria (89%, | Slipa-Archa et al. [ |
Summary of antibiotic studies
| Antibiotic | Patients/eye number | Effects | References |
|---|---|---|---|
| Cefuroxime | 2,434,008 patients/ 3,351,401 eyes | The intracameral injection of cefuroxime at the end of cataract surgery is associated with a lower risk of postoperative endophthalmitis and is safe for patients with or without a perioperative capsular rupture | Daien et al. [ |
| Gatifloxacin | 204,515 patients | Intracameral antibiotic was more effective for preventing post-cataract extraction endophthalmitis than topical antibiotic alone | Herrinton et al. [ |
| Third-generation fluoroquinolone, fourth-generation fluoroquinolone, tobramycin | 75,318 eyes | Preoperative and the operation day antibiotics have no influence on postoperative endophthalmitis rate | Rudnisky et al. [ |
| Levofloxacin 1.5% | 96 patients/96 eyes | The positive rate of conjunctival sac bacterial culture decreases from 78.1% to about 11.5%; Levofloxacin has good safety and effectiveness in conjunctival sac eradication, especially for Gram-positive bacteria, but is not as effective for Propionibacterium acnes | Suzuki et al. [ |
| Ciprofloxacin 0.3% | 46 patients/46 eyes | The administration of 0.3% ciprofloxacin significantly reduced colony-forming units compared with the control group (P < 0.05) | Carron et al. [ |
| Levofloxacin, gentamycin, chloramphenicol, fusidic acid | 464,996 eyes | Among patients treated with preoperative antibiotics and intracameral antibiotics, there were eight cases of postoperative endophthalmitis (0.017%), P = 0.29 vs. group with intracameral antibiotic alone. Addition of preoperative antibiotic does not reduce the risk of postoperative endophthalmitis | Friling et al. [ |
| Antibiotic (ofloxacin) vs. antiseptic (hexamidine di-isetionate) eye drops | 58 patients/60 eyes | Antibiotic and antiseptic eye drops had similar results in disinfection of the conjunctival sac | Vaninbroukx [ |
| Moxifloxacin 0.5% | 144 patients | The positive rate of conjunctival sac bacterial culture decreases to about 35%.1 day and 3 days of therapy with moxifloxacin had the same efficacy in decontamination of the conjunctival sac, but 1 day of prophylactic treatment with moxifloxacin resulted in a significant increase of resistance to fluoroquinolones; moxifloxacin treatment for 3 days did not cause an increase in resistance | He et al. [ |
| Moxifloxacin 0.5% | 148 patients | 93% reduction of CFU; Application of moxifloxacin on the day of surgery is effective in reducing colony-forming units | Vasavada [ |
| Gatifloxacin 0.3% vs. moxifloxacin 0.5% | 220 patients | There was no difference between the two antibiotics | Bucci et al. [ |
| Netilmicin | 56 patients/56 eyes | Coagulase negative staphylococci was positive in 9.93% of patients after treatment; 83.9% of samples had no bacterial growth; Staphylococcus aureus was eliminated after treatment | Aslan et al. [ |
| Gatifloxacin | 60 patients/120 eyes | Reduction of CFU: 67 to 28% (1 day); 60 to 37% (1 h); 67 to 18% (1 day, 1 h) | Moss et al. [ |
Summary of povidone-iodine studies (PVI)
| Analyzed chemotherapeutic | Patients/eyes number | Effects | References |
|---|---|---|---|
| 0.05% PVI | 90 patients/90 eyes | 0.05% PVI irrigation of the conjunctival sac for 30 s can achieve a low bacterial contamination rate. Importantly, it reduced the damage of the ocular surface, which is beneficial for the recovery of ocular surface function | Fan et al. [ |
| 0.3% PVI | 51 participants | Preoperative treatment with long-term, low-concentration PVI applied via a depot device to the fornix inferior seems to be an easy and effective way to reduce the number of bacterial colonies in the conjunctiva (66.7% to 23.4%) | Wass et al. [ |
| 10% PVI 3 min | 604 patients | Implementation of a preoperative prophylaxis protocol that used PVI 10% with a 3-min exposure time can be performed in clinical practice. The 3-min exposure time had no adverse sequelae | Nguyen et al. [ |
| 0.33% PVI | 99 patients/ 198 eyes | Timely iodine irrigation can serve as a simple and useful adjunctive disinfection step in cataract surgery. The bacterial DNA copy number decreased from 1.7 ± 0.5 × 103 to 1.7 ± 0.6 × 104 | Matsuura et al. [ |
| 5% PVI | 13 eyes before serial intravitreal injection; 48 cultures performed | 5% PVI solution does not increase antimicrobial resistance and has no adverse effects on the conjunctival bacterial flora | Hsu et al. [ |
| Levofloxacin 0.3% + PVI 1 vs. 5 vs. 10% | 271 patients | 10% PVI solution was most effective in the reduction of the bacterial flora in the conjunctival sac. Most common isolated bacteria were coagulase-negative Staphylococcocus spp. | Li et al. [ |
| 10% PVI drops vs. irrigation of the conjunctival sac with 1% PVI | 242 patients/263 eyes | Three drops of 10% PVI prior to surgery, followed by preoperative irrigation of the conjunctiva with 1% PVI, provides additional reduction in conjunctival sac bacterial cultures (positive rate reduced from 69–93% to 1–16%) | Nentwich et al. [ |
| 0.3% Ciprofloxacin vs. 0.3% Ofloxacin vs. 5% PVI | 164 patients/ 164 eyes | Ciprofloxacin was the most effective in bacterial eradication (72.2% to 8.0%). PVI solution (75.4% to 22.7%) was more effective than Ofloxacin (59.6% to 33.4%) | Coskun et al. [ |
| 5% PVI | 221 patients/ 224 eyes | 5% PVI is effective for the reduction of bacterial flora and reduction of bacterial growth (from 73.2 to 12.5%) | Quiroga et al. [ |
| 5% PVI solution | 54 patients/ 54 eyes | 5% PVI for 3 min significantly reduced positive cultures; A reduction of the proportion of positive swabs from 87 to 30% | Carrim et al. [ |
Moxifloxacin 5 and 5% povidone- iodine (PVI) vs. 5% PVI | 464 patients | Therapy with 5% PVI solution is effective in the reduction of positive conjunctival cultures. Adding 0.5% moxifloxacin had no significant effect in the reduction of conjunctival bacteria | Halachmi-Eyal et al. [ |
0.5% Levofloxacin (LVFL) and 1% PVI solution vs. 1% PVI solution alone | 140 patients/ 140 eyes | Levofloxacin enhanced effectiveness of irrigation of the conjunctival sac with PVI solution | Min˜o de Kaspar et al. [ |
| Levofloxacin 0.5% (LVFX) ophthalmic solution vs. 16-fold dilution of PVI solution vs. sixfold dilution of polyvinyl alcoholiodine (PAI) solution | 272 patients/ 272 eyes | 3-day therapy with LVFX and eyewash with diluted iodine solution is effective in disinfection of the conjunctival sac. It is impossible to eliminate all of bacteria from the conjunctival sac (Propionibacterium acnes and Staphylococcus epidermidis) | Inoue et al. [ |